ITC DIA Europe

Neurotrack: Transforming detection and prevention of memory loss.

Written by Roger Peverelli and Reggy de Feniks - Founders The DIA Community on Apr 23, 2018

Californian digital health startup Neurotrack is on a mission to transform the diagnosis and prevention of memory loss and related diseases like Alzheimer’s. The company’s flagship product is the Imprint™ Check-Up, a 5-minute assessment that uses eye-tracking technology to assess cognitive decline before symptoms appear. The early diagnosis of memory loss is critical for prevention of cognitive decline and this assessment is the only tool that can predict memory loss before it starts. In addition, Neurotrack offers a Cognitive Health Program that provides users with tools and advice to make lifestyle changes scientifically proven to reduce the risk of cognitive decline and diseases like Alzheimer’s.

Alzheimer’s disease is the greatest healthcare challenge of our generation. Worldwide, nearly 47 million people have Alzheimer’s or a related dementia and this number will triple by 2050. The global cost of Alzheimer’s and dementia is estimated to be $605 billion, which is equivalent to 1% of the entire world’s gross domestic product. Unfortunately, there are no disease-modifying drugs approved for Alzheimer’s to date.

At Neurotrack they believe cognitive decline and Alzheimer’s disease can be prevented and there is a solution: (1) identify people early in the disease progression and (2) prescribe a digital cognitive health program focused on diet, exercise, and cognitive training to prevent the onset of Alzheimer’s disease.

5-minute digital test
The company’s flagship product is the Imprint™ memory assessment, a 5-minute digital test using eye-tracking technology to assess memory performance over time. Along with a memory assessment tool, Neurotrack is developing a Memory Health Program that provides users with a digitally delivered, scalable, adaptable cognitive health program focused on exercise, nutrition, sleep, stress, and cognitive training. The components of this program have been scientifically validated to improve cognitive function, reduce the risk of cognitive decline, and potentially prevent the onset of Alzheimer’s disease. By tracking one’s memory over time, people have the ability to see changes in cognition early, motivating them to make lifestyle changes which can prevent or manage cognitive decline.

In the United States, Neurotrack is providing consumers direct access to these digital tools and technology to better understand, manage and track their brain health. Outside the United States, Neurotrack is working with life insurance companies to provide these tools to their customers to detect memory concerns early and prevent cognitive decline and related diseases like Alzheimer’s.

Neurotrack have recently held a proof of concept with a Japanese Insurance company and are in discussions with others.  They were awarded the Johnson & Johnson World Without Disease award of $500,000 and the the Cleveland Clinic Medical Innovation Summit award. winners in fall 2017, earning a booth at HIMSS 2018.

How it works

There are a number of pen-and-paper tests to diagnose Alzheimer’s disease and other forms of memory loss. Other companies have digitized these tests but at Neurotrack they have built the next level solution, making it possible to identify individuals earlier in the disease state than any existing technologies and in a simpler way.

Neurotrack’s solution uses eye tracking technology to identify impairment, making it possible for users can take the assessment from the comfort of their homes anywhere in the world. The app gives users a baseline test called the Imprint Memory Assessment, which takes about five minutes and can be done at home. During the test a user only has to look at the screen, and the program will track eye movements and identify potential abnormalities with recognition memory/ early signs of memory decline.

They have paired Neurotrack’s assessment solution with a digital therapeutic in order to offer the only comprehensive solution to detecting and preventing cognitive decline and Alzheimer’s disease. 

Why we selected Neurotrack for DIA Amsterdam
Cognitive decline and memory loss associated with diseases like Alzheimer’s and other dementias are a major health epidemic and so far, the healthcare industry hasn’t been successful in developing reliable tests or treatments.

Neurotracks Cognitive Health Platform helps to assess risk for memory loss and provides tools to prevent and manage cognitive decline. They offer easy and ongoing access to assessments like Imprint and tools like the forthcoming memory health program.

At DIA Amsterdam, Elli Kaplan, CEO and Co-Founder will showcase the 5-min Imprint test on a mobile phone and show their Memory Health Program.

Who is Neurotrack?
Neurotrack is founded in 2012 by Elli Kaplan and scientific co-founders Stuart Zola, and Elizabeth Buffalo leaders in the fields of neuroscience and Alzheimer’s disease. Located in Redwood City, California, they partner with world renowned clinicians.  

Key investors include Founders Fund, Social Capital, Khosla Ventures, Sozo Ventures, and others raising a total of $26.1 million.

”For me, the fight against Alzheimer’s is personal. It’s a disease that touches nearly everyone at one point in their lives, whether they’re personally diagnosed or are caring for a friend or relative with the disease. People don’t realize that cognitive decline related to Alzheimer’s can be delayed or prevented. That’s why I founded Neurotrack – to give people the tools to take control of their cognitive health.” Elli Kaplan, CEO & Co-founder Neurotrack


Amsterdam 12-13 June


00 Days
00 Hours
00 Minutes
00 Seconds
Have a look!
ITC DIA Europe - Amsterdam 2024 - Register here! Purchase now!